Due to COVID-19, regulatory agencies are relaxing guidelines and shifting priorities to address shortages in diagnostics and respiratory devices.


The current pandemic led to the one-year delay of the new European Union (EU) Medical Device Regulation (MDR), allowing authorities and manufacturers to continue under current procedures. This delay also provides more time for the European Commission to issue guidance documents. Despite this deadline extension, manufacturers should where possible continue with current plans to certify devices under MDR, as Notified Bodies (NB) are continuing to be designated under MDR. 

During uncertain times, it is necessary to understand current regulations and what it means for your development programme.

In this webinar, our regulatory and clinical experts will discuss the new challenges arising from the COVID-19 crisis and how to best navigate the regulatory landscape moving forward.

  • Impact on Notified Bodies (NBs) including the one-year delay of MDR, site audits and associated changes within the EU (UK & Brexit, Switzerland, Turkey)
  • Recap of changes to Quality Systems such as the impacts to third party internal audits and supplier audits
  • Considerations for EU and U.S. clinical studies including: CE marking versus U.S. approval processes, emergency use authorisation and flexibility in timing and sterilisation concerns 

Target audience

Medical device and IVD manufacturer personnel from R&D, Clinical Operations, manufacturing, Quality Assurance, Regulatory Affairs, Executive/Management and Sales/Marketing

On-Demand Webinar Archive

To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.

Access Webinar Archive


Angela Brown, B.S.

Director, Regulatory Affairs, ICON plc

Angela has over 20 years of regulatory affairs and quality assurance experience with various products in the medical device industry specialising in international regulatory affairs working with universities, start-up and blue chip companies.  Her expertise reflects her ability to successfully navigate country specific requirements by providing strategic global regulatory strategies and submissions bringing new and existing products to the marketplace outside the US including EU, Canada, South & Latin America, Middle East, Asia, and Africa, as well as the US.

She is experienced in transitional regulatory activities to handle the ever-changing global regulatory environment.  Angela has a comprehensive knowledge of the regulations for the preparation and writing required for global medical device submissions including EU Technical Documentation (Technical Files/Design Dossiers), Canadian Licensing and Submissions, TGA Technical Documentation, International Product Dossiers, and JSTED, as well as US premarket submissions. Additionally, her expertise in quality assurance provides quality management system alignment as additional geographic regions are incorporated, specifically in post market activities including complaint management, adverse event reporting and recall management. 

Angela has held various levels of responsibility in regulatory and quality throughout her career prior to joining ICON in 2018.  She is an active member of the Regulatory Affairs Professional Society (RAPS), The Organization for Professionals in Regulatory Affairs (TOPRA), and holds a B.S. in health science from Campbell University.